Graft-Versus-Tumour Effect Following Allogeneic Haematopoietic Stem Cell Transplantation in a Paediatric Patient With Mogamulizumab-Treated Primary Cutaneous Peripheral T-Cell Lymphoma. (PubMed, EJHaem) - Sep 30, 2026 - "Despite a 60-day washout period, he developed prolonged steroid-refractory acute graft-versus-host disease requiring ruxolitinib and extracorporeal photopheresis. This case underscores the need to optimise allo-HSCT timing after mogamulizumab and preserve graft-versus-lymphoma effect while limiting graft-versus-host disease. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission."
Journal • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cutaneous T-cell Lymphoma • Graft versus Host Disease • Hematological Malignancies • Immunology • Lymphoma • Oncology • Pediatrics • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Transplantation
|
|
Hanne V Marquart; Hilde Uhlving; Lene D Sjö; Lisa Hjalgrim; Lone Skov; Maria Ebbesen Sørum; Marianne Ifversen; Peter Pontoppidan; Signe Modvig; Tania Masmas
|